Ann: Kazia change in directors interests, page-26

First 26 Last

Share
Profile

Follow
cane7

4,133 Posts.

275

01/09/20

12:08

Post #: 46985045
Share

Originally posted by rikki: ↑

that’s very incorrect:

anyone taking up the the last two CRs is effectively 275% up today! - .40 to 1.10 today!!!

we own two products Cantrixil and Paxalisib hence the negotiations with partners for lic deals and all our swag of partner trials at little or no cost to Kazia - starting to report news we all knew was coming and hence the radical re-rating of SP and with much more on the way.

thank god james came onboard and thank god he had the capability to drive and secure ownership of Paxalisib and thank god he is able to recognise the requirement for and has driven a restructure that delivers so much value driving us to a MC of 100+ million

still in the foot hills now but nice to see SPs at $1+ and heading toward $2 in the next couple of readouts.

———

if this is a lottery ticket then you should be so lucky as to acquire that ticket when entering a phase 3 pivotal study for FDA approval which even our conservative management predicts a 85% chance of approval!!!

in other-words - well well more likely than not at this late stage.

a potential 85% successful lottery ticket is a ticket you’d be mad not to own all you can of....

I don’t think ‘lottery’ is the right descriptor when a thing is more likely than not... particularly when you are referring to the new standard of care in GBM and DiPG (by definition of DiPG having no treatment at all).

lets flip that around and call it properly based on % as ...

“A sure thing, less maybe 15% a sure thing”

for GBM alone...

+ DiPG + brain Mets + more

Expand

rikki, great post!! Gee i,m making 140,000 already , lets GO !!!!

KZA Price at posting: $1.09 Sentiment: Buy Disclosure: Held
4 Upvote

1 Great analysis

Reply

Top Stories

LLC

Lendlease sells off US east coast construction operations in latest global divestment push

PYC

PYC achieves key designation for drug aiming to treat blinding eye disease ADOA

Consumer Staples Shine Amid Retail Slump – Key Stocks to Watch

TBN

Tamboran kicks off Shenandoah South pilot project with SS-2H well spud

CCO

The Calmer Co’s Anthony Noble reflects on record breaking FY24

HLX

Helix investor makes partial takeover bid, proposing board changes

Week 35 Wrap: HotCopper’s top watched; ‘iron ore winter’ has started; Oz inflation @ 3.5% MoM; Harris fracking flip

CYM

WA Nifty copper project steps closer to restart with Cyprium Metals inking $40M loan from Glencore

HVN

Consumers cautious according to Harvey Norman, as profit slumps 35% in FY24

VYS

Vysarn acquires Waste Water Services Pty Ltd for $7.5M; WWS to become subsidiary as expansion continues